In order to study efficacy, toxicity and the long-term results of donor lymphocyte infusions (DLI), we retrospectively analyzed DLI given for relapse after conventional allogeneic hematopoietic stem cell transplantation (HSCT) in 30 patients with a median delay of 107.5 months after transplant and 58 months after DLI. After DLI, 15 patients established full donor chimerism, three patients developed grade III and one grade IV acute GVHD. A total of 15 patients achieved a disease response. Among the 14 patients with chronic myeloid leukemia (CML), 11 are alive at the last follow-up: five are in complete molecular response (CMR) and two in complete cytogenetic response (CCR) with no other intervention after DLI, three in CMR after imatinib mesylate given after DLI and one in complete hematological response after imatinib mesylate and reduced-intensity conditioning allogeneic SCT performed after DLI. At the time of the last follow-up, 19 (63%) patients died and 11 (37%) remain alive. The 3-year probability of survival for the entire population, CML patients and non-CML patients, was 60, 93, 62% after transplantation, and 48, 80 and 48% after DLI, respectively. A multivariate analysis demonstrated a significantly worse survival rate after transplantation for female recipients, advanced disease and acute leukemia before transplantation. 8-9 DLI have also been used for other malignant diseases relapsing after allogeneic HSCT but with less success. [10] [11] [12] Besides their benefit, DLI can induce severe and sometimes life-threatening complications such as acute and chronic graft-versus-host disease (GVHD) or pancytopenia.
In order to study efficacy, toxicity and the long-term results of donor lymphocyte infusions (DLI), we retrospectively analyzed DLI given for relapse after conventional allogeneic hematopoietic stem cell transplantation (HSCT) in 30 patients with a median delay of 107.5 months after transplant and 58 months after DLI. After DLI, 15 patients established full donor chimerism, three patients developed grade III and one grade IV acute GVHD. A total of 15 patients achieved a disease response. Among the 14 patients with chronic myeloid leukemia (CML), 11 are alive at the last follow-up: five are in complete molecular response (CMR) and two in complete cytogenetic response (CCR) with no other intervention after DLI, three in CMR after imatinib mesylate given after DLI and one in complete hematological response after imatinib mesylate and reduced-intensity conditioning allogeneic SCT performed after DLI. At the time of the last follow-up, 19 (63%) patients died and 11 (37%) remain alive. The 3-year probability of survival for the entire population, CML patients and non-CML patients, was 60, 93, 62% after transplantation, and 48, 80 and 48% after DLI, respectively. A multivariate analysis demonstrated a significantly worse survival rate after transplantation for female recipients, advanced disease and acute leukemia before transplantation. 6 This antitumor effect has been well established in CML patients relapsing after allogeneic HSCT 7 and numerous studies have subsequently confirmed that DLI can induce complete cytogenetic and even molecular remissions. [8] [9] DLI have also been used for other malignant diseases relapsing after allogeneic HSCT but with less success. [10] [11] [12] Besides their benefit, DLI can induce severe and sometimes life-threatening complications such as acute and chronic graft-versus-host disease (GVHD) or pancytopenia. [13] [14] These complications were seen mainly in DLI using bulk-dose (BD) regimens most frequently and containing a high number of CD3 þ T cells. 15 Two approaches have been introduced to reduce DLI complication incidence: one based on CD8 þ lymphocyte selective depletion 16 and the other based on initial infusion of low numbers of T cells followed by escalating increased doses at variable intervals (escalating dose (ED) regimen). 15 Moreover, to develop DLI in the treatment of relapse after HSCT, another important question was the DLI response durability. [17] [18] The long-term efficacy and toxicity of such a procedure have not been well documented so far. Nevertheless Dazzi et al 19 showed a correlation between longterm survival and molecular remission achievement after DLI. The principal aim of our study was to analyze the long-term outcome after DLI given for relapse of hematological malignancies after conventional HSCT from sibling and unrelated donors.
Patients and methods

Patient characteristics and transplant procedures
In all, 19 male and 11 female patients were studied (total ¼ 30). The median age was 34 years (range 17-47). The conditioning regimens were either cyclophosphamide (60 mg/kg/day Â 2 days) and total body irradiation (TBI) of 12 Gy or cyclophosphamide (50 mg/kg/day Â 4 days) and busulfan (4 mg/kg/day Â 4 days). A total of 27 patients underwent allogeneic transplants from HLA-identical sibling donors, two from unrelated fully HLA-identical donors and one from a one-antigen-mismatched unrelated donor. The diagnoses before transplantation were 14 chronic myeloid leukemias, nine acute myelogenous leukemias (AML), four acute lymphoblastic leukemias (ALL), one non-Hodgkin lymphoma (NHL), one myelodysplasia (MDS) and one multiple myeloma (MM). DLI were used for hematological relapse in 26 patients (11 CML, three ALL, nine AML, one MDS, one NHL and one MM) (87%), central nervous system relapse in one patient (ALL) and cytogenetic relapse in three patients (CML). The median delay between allotransplantation and relapse was 24 months (range, 0.3-113). A total of 27 patients received one transplant and three patients (one ALL, two CML) two transplants. All patients received unmanipulated bone marrow as HSC source. Initial GVHD prophylaxis consisted of intravenous cyclosporine A (CsA) and methotrexate (days 1, 3 and 6).
DLI regimen
Lymphocytes were harvested from 27 HLA sibling donors and from three unrelated donors without previous growth factor administration. In our unit, the 27 sibling donors were harvested and lymphocytes were further fractionated (as far as possible) in order to cryopreserve doses of 1 Â 10
þ cells/kg in 22 cases. We discontinue immunosuppression almost 2 weeks prior to DLI administration. The median interval between relapse and lymphocyte infusion was 1.9 months (range, 0-52). In all, 10 patients received a single dose that varied from 0.1 to 2.64 Â 10 8 CD3/kg and among them five patients received a BD (three 1 Â 10 8 CD3/kg; one 2.53 Â 10 8 CD3/kg and one 2.64 Â 10 8 CD3/kg). Knowledge of the relation between complications and BD led us to change our DLI strategy by giving ED and the 20 patients followed received ED varying from 0.01 to 3 Â 10 8 CD3/kg. All AML patients have received intensive chemotherapy including high dose of cytosine arabinoside, the four ALL patients an association of mitoxantrone and cytosine arabinoside and the NHL patient an association of etoposide, daunorubicine, cytosine arabinoside and methyl-prednisolone. No durable CR or PR was observed. The interval between chemotherapy and DLI was at least 2 months. MDS, MM and CML patients received DLI without any chemotherapy previously.
Evaluation of disease response and chimerism after DLI
After DLI, clinical, hematological, cytogenetic and molecular responses were assessed as well as chimerism. Chimerism was initially determined using polymerase chain reaction of a variable number of tandem repeat (VNTR) sequences. Peripheral blood and bone marrow aspirates were analyzed. After extraction, DNA was amplified with specific primers located in flanking regions of VNTRs. After electrophoresis, PCR products were analyzed on a colored gel (Sybr Green, fabriquant, localisation) under UV light. A semiquantitative study was conducted for each donor/recipient pair and each informative VNTR. Mixed chimerism was defined as the presence of at least 5% recipient cells. From 1999 to 2003, chimerism analysis was performed with the short tandem repeat method (STRs) with promega multiplex kits (CTTV, FFFL and gamma STR, fabriquant, localisation) based on fluorescent analysis of repetitive sequences. After amplification with specific primers, PCR products were analyzed on ABI 310 (Applera). Profiles obtained for each informative system were screened through the genescan program in comparison with the memorized profile from donor and recipient analyzed before transplantation. Peak areas gave us the percentage of recipient cells for each sample. 20 Mixed chimerism (MC) was also defined by the presence of at least 5% recipient cells. For CML, cytogenetic responses were evaluated by conventional karyotyping analysis (R Banding) and molecular responses by BCR-ABL transcript detection using a quantitative RT-PCR method.
Statistical analysis
In the framework of survival analysis, Kaplan-Meier estimates were used to estimate overall survival after transplant and after DLI. For multivariate analysis, the Cox proportional hazards model was used. The multivariate analysis considered before DLI: age, sex, disease status at transplantation (CR vs PR vs refractory disease or relapse), type of disease (all diseases vs CML), conditioning (TBI or no TBI) and after DLI: acute GVHD and chronic GVHD, chimerism status (full donor chimerism (FDC) vs MC) and disease response. Outcome measure was overall survival.
Results
The median interval between transplantation and relapse, transplantation and DLI, and relapse and DLI were 24, 28 and 1.9 months, respectively. The median follow-up was 107.5 months (range, 69-84) after transplantation and 58 months (range, 29-36) after DLI.
GVHD
Four patients developed acute GVHD: three grade III, one after a single dose and two after ED and one grade IV after BD. Three of these patients had FDC and only one MC. Two cases of grade III acute GVHD developed extensive chronic GVHD (cGVHD). One patient developed de novo limited cGVHD after ED. Acute and chronic GVHD incidence and severity after DLI are shown in Table 1 .
Chimerism study
A total of 27 patients (90%) presented MC before DLI and 15 (55%) (one NHL, two ALL, two AML, 10 CML) established FDC after DLI. To establish FDC, we infused two doses, three BD and 10 ED. The median number of DLI patients to obtain chimerism conversion was two (range, 1-5) after a median interval of 3.5 months (0. . At last follow-up, among the 11 long-term survivors, 10 remained in FDC and only one was in MC (patient 16, 29% recipient cells). Chimerism data are shown in Table 2 and chimerism progression after DLI in Figures 1 and 2 .
Disease response after DLI After DLI, among 30 patients, 15 (50%) achieved a disease response. Of these 15 DLI responders, 13 showed FDC and two persistent MC. Of 14 CML patients, two (14%) (1/3 cytogenetic relapse and 1/11 hematological relapse) achieved a complete hematological response (CHR), nine (64%) (2/3 cytogenetic relapse and 7/11 hematological relapse) achieved a complete cytogenetic response (CCR) and 5/9 achieved a complete molecular remission (CMR) (2/3 cytogenetic relapse and 3/11 hematological relapse) and three remained in chronic phase (CP). Among acute leukemia patients, 3/13 (23%) achieved complete remission (CR) and one partial remission (PR), and the NHL patient presented CR. The median number of DLI patients to obtain these responses was two (range, 1-5), with a median interval between two DLI of 1.5 months. Of the 11 CML responders with a median follow-up of 58 months (range, 29-96) after DLI, one of the two reaching CHR achieved CCR and the other relapsed in CP and achieved a CMR after imatinib mesylate. Of the nine who reached CCR, five have achieved CMR and one remained in CCR after DLI without any other intervention, three relapsed in CP (one achieved CMR after imatinib mesylate, one CHR after IFN þ imatinib mesylate and reduced-intensity allogeneic stem cell transplantation and one remained in CP despite a second myeloablative allotransplantation) (Figure 3) . Among the three patients remaining in CP after DLI, only one patient achieved CMR after imatinib mesylate. Among the three acute leukemia patients who responded after DLI, one patient remained in CR and the NHL patient relapsed. Disease responses after DLI and chimerism before and after DLI are shown in Table 2 .
Survival after DLI
Of the 30 patients, 19 (63%) died and 11 (37%) are alive, with a median follow-up of 107.5 months (range, 69-184) after allotransplantation and 58 months after DLI (range, 29-96). Among the 14 CML patients, 11 (78%) are alive at the last follow-up: five are in CMR and two in CCR with no other intervention after DLI, three in CMR after imatinib mesylate and one in CHR after imatinib mesylate and allogeneic HSCT after reduced-intensity conditioning (RICT). The 3-year probability of survival for the entire population after transplantation was 60% (95% CI (45-80%)) and 48% (95% CI (30-60%) after DLI (Figure 4a and b). When considering only CML patients, the overall survival was better with a 3-year probability of survival of 93% (95% CI (79-100%)) after allotransplantation and 80% (95% CI (60-100%) after DLI. Among the 11 CML survivors at last follow-up, eight were in CMR. When we considered patients with other diseases than CML, the 3-year probability of survival after transplantation was 62% (95% CI (44. 
Discussion
Allogeneic HSCT was the only curative approach for some hematological malignancies but relapse remained a problem and a challenging situation that is still controversial when considering treatment. To improve the outcome of patients who relapsed after allogeneic HSCT, many therapeutic options were explored such as a second transplant, 2 immunotherapy, [21] [22] growth factors, [23] [24] [25] DLI, imatinib mesylate 26 and finally monoclonal antibodies. [27] [28] Many authors have shown that DLI have been used effectively to induce the GVT [29] [30] effect in patients who relapsed after allogeneic HSCT. It was demonstrated that response to DLI is closely related either to the disease status or the kind of relapse before DLI. 31 This alloreactive strategy provided responses at the cytogenetic or molecular level correlated with a total donor chimerism conversion. These benefits were at the price of complications such as GVHD and pancytopenia. 13 Two types of DLI were explored, including either single BD or ED given at variable intervals. DLI toxicity without GVL effect reduction 15 was observed after ED and in addition, Guglielmi et al 32 demonstrated the impact of initial cell Table 3 ).
dose (ICD) on DLI toxicity, disease response and survival after DLI. Many issues remain unsettled, including DLI timing after transplantation, DLI doses and the durability of response after DLI. Our principal aim was to study the long-term outcome after DLI given for relapse after HSCT.
In comparison with Dazzi's series, 19 studying the follow-up of relapsed CML patients after DLI, we observed a difference in the interval between transplantation and relapse (24 months for our series vs 12 months) and the interval between relapse and DLI (1.9 months vs 10 months). Despite the short interval between relapse and DLI in our series, we observed no increase in incidence of severe GVHD in comparison to others. We observed no influence of DLI administration type on GVHD incidence and severity. At 3 years, we showed for CML patients a survival probability of 93%, similar to the survival rate of CML molecular responders after DLI observed by Dazzi et al, 19 who moreover demonstrated a correlation between the quality of response to DLI and survival. When we considered patients with diseases other than CML, the 3-year probability of survival after transplantation was only 62% because of the well-known worse GVL effect observed after DLI in other diseases than CML, particularly in ALL. 10 In our series, the 11 long-term survivors were all in complete continuous remission at the last followup, eight were in CMR but only five had only received DLI with no other therapeutical intervention during their Long-term follow-up after DLI given for relapse after myeloablative allogeneic HSCT AS Michallet et al follow-up. Among these five CMR patients, three were in hematological relapse (3/11) and two in cytogenetic relapse (2/3) before DLI, which again demonstrated a better response when DLI was performed earlier. 31 As previously described 4, [7] [8] [9] [10] 14, 19, 33 CCRs were observed in our series in CML patients, which confirmed once again the real sensitivity of CML patients to adoptive cell immunotherapy. The maximal follow-up after DLI of 96 months (our series) and 72 months (Dazzi's series 19 ) is an important argument for the curative power of DLI for CML relapse after allogeneic transplantation. Strangely, we demonstrated in the multivariate analysis a significantly worse survival after transplantation for female recipients but, when we considered the age of the population, female subjects (median age: 36.5 years) were older than male 3-year probability of overall survival after transplantation for the whole population was 60% (95% CI (45-80%)). When considering only CML (line -in the figure) patients, the 3-year probability of survival was 93% (95% CI (79.36-100%)); (b) After DLI, the 3-year probability of overall survival of the whole population was 48% (95% CI (30-60%)) and 80% (95% CI (60-100%)) when considering only CML patients. subjects (median age: 28.5 years), which could explain this observation.
Until now, because of these observed results, DLI remains the only curative therapy in this situation and has to be compared to other promising treatments such as imatinib mesylate, which permits molecular remission and chimerism conversion when given for CML relapse after HSCT. 34 Vela-Ojeda et al 35 have observed that interferon a potentiate the GVL effect of DLI in some CML patients. This study showed that DLI could clearly induce a longterm GVT effect in CML patients. Consequently, CML relapse after HSCT remains an indication of choice for this adoptive immunotherapy, but early relapse detection by molecular monitoring and chimerism kinetics may improve DLI management, decreasing their potential toxicity and increasing their efficacy. In addition, imatinib mesylate efficacy has to be confirmed in long-term follow-up studies and needs prospective trials. Moreover, a new therapeutic strategy combining imatinib mesylate, allogeneic transplantation and DLI could induce interesting and durable responses in advanced CML or Philadelphia-positive acute lymphoblastic leukemia. 36 
